In this episode I’ll discuss prostate cancer and PET. Prostate imaging with PET remains unapproved for reimbursement by CMS, and we’ll examine several reasons why this is the case. One of the major limitations has to do with the tracers available, and along those lines I’ll talk about radiopharmaceuticals currently under investigation.